PA
GPCR icon

Profund Advisors’s Structure Therapeutics GPCR Stock Holding History

Profund Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,507
Closed -$244K – 1170
2025
Q4 		$244K Buy
+3,507
New +$143K 0.01% 1026

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Profund Advisors's GPCR Position: Q1 2026 in Review

Profund Advisors sold out of Structure Therapeutics (GPCR) in Q1 2026, closing a stake of 3,507 shares — an estimated $244K sold.

Profund Advisors first reported a position in GPCR in Q4 2025 and held it in 1 quarter. The position peaked at $244K in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Profund Advisors reported no remaining Structure Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Profund Advisors sold 3,507 Structure Therapeutics shares in Q1 2026, an estimated $244K.
  • Profund Advisors first reported a position in Structure Therapeutics in Q4 2025 and held it in 1 quarter.
  • Profund Advisors's Structure Therapeutics position peaked at $244K in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.